Intensive 4-week postoperative multimodal rehab after proximal pancreatic surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

REACT is a prospective, single-center, single-cohort feasibility study evaluating a 4-week intensive rehabilitation program started after severe postoperative complications following proximal pancreatic resection (pancreatoduodenectomy or total pancreatectomy). All participants receive the multimodal intervention in addition to standard care, with no control group. The program targets physical recovery, nutrition, and metabolic support to address muscle loss, malnutrition, and reduced function that can follow pancreatic surgery. Eligibility includes adults who had elective proximal pancreatic resection and developed a severe complication (CCI > 21) during stay in a Milan hospital. The study is conducted at IRCCS Ospedale San Raffaele in Milan, Italy.

Why it matters

Who can join: the full rules

* Inclusion Criteria:
* Age ≥18 years.
* Patients undergoing elective proximal pancreatic resection (pancreatoduodenectomy or total pancreatectomy).
* Patients developing a severe postoperative complication during their hospital stay, defined as a Comprehensive Complication Index (CCI) \>21.
* Exclusion Criteria:
* Metastatic disease.
* Surgical procedures other than pancreatoduodenectomy or total pancreatectomy.
* Inability to speak Italian.
* Cognitive impairment or illiteracy resulting in inability to read and understand the Italian language.
* Medical conditions contraindicating the rehabilitation regimen (exercise and nutritional intervention), including orthopedic or cognitive disabilities and chronic renal failure (dialysis or creatinine \>250 mmol).
* Pregnancy.

Where it's running

• Ospedale San Raffaele
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Nicolò pecorelli
• Email: pecorelli.nicolo@hsr.it
• Phone: 0226437810

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New lipase NHS7108 safety and potential efficacy in adults with exocrine pancreatic insufficiency

  A 2-period study tests whether the new lipase NHS7108 works safely for adults with EPI by comparing it to the standard pancrelipase (Zenpep) at several doses over 14 days each.

  Recruiting at 7 sites Phase 2 Société des Produits Nestlé (SPN) · Scottsdale, Arizona and 38 other locations · NCT07559175

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Early diagnosis of pancreatic cancer using duodenal fluid biomarkers

  This project will see if pancreatic fluid collected during routine endoscopy can help detect early pancreatic cancer in adults.

  Recruiting at 3 sites Asan Medical Center · Aurora, Colorado and 2 other locations · NCT07030348

• Paracetamol with ibuprofen versus paracetamol with metamizole for pain in children with acute pancreatitis

  We will test whether IV paracetamol combined with ibuprofen or IV paracetamol combined with metamizole reduces pain more effectively in children aged 3–18 with acute pancreatitis.

  Recruiting Phase 4 Medical University of Warsaw · Warsaw · NCT07024199

• Using Ondansetron to Prevent Pancreatitis After ERCP

  This study is testing if the medication ondansetron can help prevent pancreatitis in adults who are having an ERCP procedure.

  Recruiting Phase 3 Tanta University · Tanta · NCT06861010

• New navigation system for endoscopic ultrasound in pancreatic disease

  This study is testing a new navigation tool for endoscopic ultrasound to see if it helps doctors find and examine pancreatic problems more accurately and quickly for patients with pancreatic disease.

  Recruiting IHU Strasbourg · Strasbourg · NCT06798545

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.